Charles Schwab’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-147,863
Closed -$8.84M – 3376
2020
Q2
$8.84M Buy
147,863
+31,143
+27% +$1.92M ﹤0.01% 1721
2020
Q1
$6.93M Buy
116,720
+1,652
+1% +$96.3K ﹤0.01% 1660
2019
Q4
$6.3M Buy
115,068
+47,333
+70% +$1.77M ﹤0.01% 1902
2019
Q3
$1.91M Buy
67,735
+5,968
+10% +$219K ﹤0.01% 2392
2019
Q2
$2.05M Buy
61,767
+17,237
+39% +$538K ﹤0.01% 2363
2019
Q1
$1.51M Buy
44,530
+1,051
+2% +$33.4K ﹤0.01% 2441
2018
Q4
$1.19M Buy
+43,479
New +$1.12M ﹤0.01% 2488

Other funds holding PRNB

Charles Schwab's PRNB Position: Q3 2020 in Review

Charles Schwab sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 147,863 shares — an estimated $8.84M sold.

Charles Schwab first reported a position in PRNB in Q4 2018 and held it in 7 quarters. The position peaked at $8.84M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Charles Schwab reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Charles Schwab sold 147,863 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $8.84M.
  • Charles Schwab first reported a position in Principia Biopharma Inc. Common Stock in Q4 2018 and held it in 7 quarters.
  • Charles Schwab's Principia Biopharma Inc. Common Stock position peaked at $8.84M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Charles Schwab's 13F filing for Q3 2020, filed 13 Nov 2020.